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Background/aims: Hypersensitive pain response is often observed in patients with 
Parkinson’s disease (PD); however, the mechanisms responsible for hyperalgesia are not 
well understood. Chronic neuroinflammation is one of the hallmarks of PD pathophysiology. 
Since the midbrain periaqueductal gray (PAG) is an important component of the descending 
inhibitory pathway controlling on central pain transmission, we examined the role for pro- 
inflammatory cytokines (PICs) system of PAG in regulating exaggerated pain evoked by PD.
Methods: We used a rat model of PD to perform the experimental protocols. PD was 
induced by microinjection of 6-hydroxydopamine to lesion the left medial forebrain bun-
dle. Pain responses to mechanical and thermal stimulation were first examined in control 
rats and PD rats. Then, ELISA and Western Blot analysis were used to determine PIC 
levels and their receptors expression.
results: Protein expression of IL-1β, IL-6, and TNF-α receptors (namely, IL-1R, IL-6R, 
and TNFR subtype TNFR1) in the plasma membrane PAG of PD rats was upregulated, 
whereas the total expression of PIC receptors was not significantly altered. The ratio 
of membrane protein and total protein (IL-1R, IL-6R, and TNFR1) was 1.48 ±  0.15, 
1.59 ± 0.18, and 1.67 ± 0.16 in PAG of PD rats (P < 0.05 vs. their respective con-
trols). This was accompanied with increases of PICs of PAG and decreases of GABA 
(623 ± 21 ng/mg in control rats and 418 ± 18 ng/mg in PD rats; P < 0.05 vs. control rats) 
and withdrawal thresholds to mechanical and thermal stimuli. Our data further showed 
that the concentrations of GABA and withdrawal thresholds were largely restored by 
blocking those PIC receptors in PAG of PD rats. Stimulation of GABA receptors in PAG 
of PD rats also blunted a decrease in withdrawal thresholds.
conclusion: Our data suggest that upregulation of the membrane PIC receptor in 
the PAG of PD rats is likely to impair the descending inhibitory pathways in regulating 
pain transmission and thereby plays a role in the development of hypersensitive pain 
response in PD.
Keywords: mechanical sensitivity, thermal sensitivity, neurodegeneration, central inhibition
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inTrODUcTiOn
Parkinson’s disease (PD) is characterized by the loss of central 
dopaminergic (DA) neurons and the presence of α-synuclein-
containing aggregates in the substantia nigra pars compacta (1). 
Notably, epidemiological studies indicate that a high frequency 
of hypersensitive pain is presented in PD patients (2, 3). Also, 
behavioral studies show that sensitivity to pain is increased in 
patients (4, 5). Central nervous mechanisms are considered to play 
an important role in processing abnormalities in pain response in 
PD patients (6). Non-DA neurotransmission has been implicated 
in influencing descending pain pathways at central levels (6). 
Nonetheless, treatment options for these abnormal pain sensa-
tions have been limited, partly because of our poor understand-
ing of the neural mechanisms responsible for PD-induced pain. 
Thus, it is significant to investigate the pathophysiology of pain 
abnormalities in patients with PD.
As a component of the descending pain modulatory network, 
the midbrain periaqueductal gray (PAG) has an inhibitory or 
excitatory control on pain transmission via the rostral ventro-
medial medulla, projecting to the spinal and medullary dorsal 
horn (7–9). Accordingly, in the present study, we examined the 
underlying mechanisms by which the changes in neural substrate 
activity in the PAG are engaged in PD-induced pain.
Chronic neuroinflammation is one of the hallmarks in PD 
(10, 11). Studies in human PD patients and animal models of 
experimental PD show that activation of glial cells and eleva-
tion of pro-inflammatory cytokines (PICs, i.e., IL-1β, IL-6, and 
TNF-α) levels are common features of the PD brain (12–15). 
Chronic release of PICs by stimulated astrocytes and microglia 
leads to the exacerbation of DA neuron degeneration in the sub-
stantia nigra pars compacta (13, 15). Also, peripheral immune 
system is involved in the pathogenesis of PD. Infiltration and 
accumulated immune cells from the periphery are identified in 
and around the affected brain regions of PD patients (13, 15). 
Moreover, inflammatory processes have been suggested as 
promising interventional targets for PD and even other neuro-
degenerative diseases (12, 13, 14, 15). A better understanding 
of the role of inflammation in PD will provide new insights 
into the pathological processes and help to establish effective 
therapeutic strategies.
GABA is a main inhibitory neurotransmitter in the central 
nerve system in control of neuronal excitability. After GABA 
release from presynaptic terminals, GABA transporters play a 
role in regulating a rapid removal of extracellular GABA (16, 17), 
which thereby leads to ending of inhibitory synaptic transmis-
sion. Thus, this mechanism is responsible for GABA spillover to 
neighboring synapses (16, 18) and GABA homeostasis (16, 19). 
In contrast, under certain pathological and physiological condi-
tions, the abnormal levels of GABA are observed (20, 21). A 
recent study suggests that PIC pathways are upregulated in the 
brain of rats with excitatory neuronal activities, and this alters 
expression of GABA via IL-1β and TNF-α receptors (22).
Therefore, in this study, we determined the levels of IL-1β, 
IL-6, and TNF-α and their receptors expression in PAG tissues 
of PD rats and control rats. Also, we examined if PIC pathways 
are involved in pain response in PD via the descending pain 
modulatory mechanisms. We hypothesized that protein expres-
sion of PIC receptors is upregulated in the PAG of PD rats, and 
blocking PIC receptors in the PAG attenuates amplified pain 
responses in PD via GABAergic inhibitory pathways.
MaTerials anD MeThODs
animals
The Research Administration Animal Committee of Liaocheng 
People’s Hospital approved the procedures outlined in this study 
(#AS0122015), which were compliant with the guidelines of the 
International Association for the Study of Pain. One hundred 
twenty-one male Sprague-Dawley rats weighing 150–200 g were 
used in this study. The rats were housed in individual cages with 
free access to food and water and were kept in a temperature-
controlled room (25°C) on a 12/12 h light/dark cycle.
induction of PD by 6-hydroxydopamine 
lesions
Animals were anesthetized by sodium pentobarbital (60 mg/kg, 
i.p., Sigma Co.) and then placed in a David Kopf stere-
otaxic instrument. Injections of 6-hydroxydopamine (6-OHDA) 
(7 μg/2 μl/each location, dissolved in saline containing 0.02% 
ascorbic acid) were made at two locations into the left medial 
forebrain bundle. Stereotaxic coordinates for the lesions were 
3.3 mm rostral to the interaural line, 1.4 mm left of the midline, 
and 6.5 and 6.8 mm (2 μl each location) ventral to the dural sur-
face. The 6-OHDA solution was administered through a cannula 
using a microinjection pump at a rate of 1 μl/min. The cannula 
was left in place for 5  min after completion of each injection 
and then slowly retracted. Equivalent injections of saline were 
made in control animals. Note that 30 min prior to surgery, rats 
received an intraperitoneal injection of desipramine hydrochlo-
ride (20 mg/kg, i.p., Sigma Co.) to protect noradrenergic neurons 
and fibers.
rotation Behavior Test
Two weeks after 6-OHDA injection, rats injected with 6-OHDA 
and control rats with saline injection were placed in a cylindri-
cal container (300 mm diameter). Methamphetamine (3 mg/kg, 
i.p.) was injected to trigger rotational behavior. The rotational 
behavior was counted at 10-min intervals for 60  min after 
methamphetamine administration. Animals with >7 turns/min 
of rotational behavior were included in the study, as DA neurons 
and fibers of those rats are destroyed after 6-OHDA lesions (23).
Pag cannulation and Drug infusion
Then, 3  days were allowed before the experiments. Rats were 
implanted with a stainless steel guide cannula (0.8  mm, o.d.) 
with sodium pentobarbital (60 mg/kg, i.p.), and then the guide 
cannula was secured to the skull. Stereotaxic coordinates for 
the dorsolateral PAG (dl-PAG) were 7.6  mm posterior to the 
bregma, 0.65 mm lateral to the midline, and 4.2 mm ventral to 
the brain surface.
Following this, cannula was connected to an osmotic min-
ipump (Alzet pump brain infusion kit, DURECT Inc., Cupertino, 
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CA, USA) with polycarbonate tubing. The pumps were placed 
subcutaneously between the scapulae and loaded with vehicle 
[artificial cerebrospinal fluid (aCSF)] as control or each PIC 
receptor antagonists, namely IL-1Ra (IL-1β receptor antagonist), 
SC144 (gp130 antagonist to block IL-6R), and etanercept (TNF-α 
receptor antagonist) (Tocris Co., Ellisville, MO, USA). In a sub-
group, muscimol, agonist of GABAa receptors was loaded. The PIC 
receptor antagonists in 10 μM of concentration and muscimol in 
100 μM of concentration were delivered at 0.25 μl/h (Alzet Model 
1003D/3-day-delivery DURECT Inc., Cupertino, CA, USA). This 
intervention allowed animals to receive continuous PAG infusion 
via the osmotic minipumps before the experiments, and brain 
tissues were taken out. Note that all drugs were dissolved in aCSF 
as a final concentration.
Pain sensitivity
Rats were placed in individual plastic boxes to acclimate for 
>30 min in order to quantify the mechanical sensitivity of the 
hind paw. Mechanical withdrawal threshold (PWT) of rat hind 
paw responding to the stimulation of von Frey filaments was 
examined. A series of calibrated von Frey filaments (ranging from 
0.5 to 18.0 g) were applied perpendicularly to the plantar surface 
of the hind paw with a sufficient force to bend the filaments for 
60 s or until paw withdrew. If a response was seen, the filament 
of next lower force was given. Without a response, the filament 
of next greater force was used. To avoid injury during tests, the 
cutoff strength of the von Frey filament was 18  g. The tactile 
stimulus producing a 50% likelihood of withdrawal was deter-
mined using the “up-down” method (24). Each test was repeated 
twice at roughly 2 min intervals. The mean value was used as the 
force producing a withdrawal response.
Rat withdrawal latency (PWL) to a radiant heat was measured 
to examine thermal hyperalgesia. Rats were positioned separately 
in cages on an elevated glass platform and allowed for 30  min 
acclimation. Each hind paw received three stimuli with a 10 min 
interval, and the mean of the three withdrawal latencies was 
defined as PWL. The heat was maintained at a constant intensity. 
To prevent tissue damage, the cutoff latency was set at 20 s. All the 
behavioral tests were performed in a blind style.
At the end of the experiments, 2% Evans Blue in 0.25 μl was 
infused through the cannula. Then, the animals were anesthe-
tized by sodium pentobarbital and intra-cardiacally perfused 
with physiological saline followed by 4% of paraformaldehyde 
solution. The midbrain was sectioned, and the location of injec-
tion sites was verified by histological examination of blue dye 
according to the atlas of Swanson (25). The rats were included for 
data analysis with microinjection site that was localized within 
the dl-PAG.
elisa Measurements
The rats were first euthanized by overdose sodium pentobar-
bital (120  mg/kg, i.p.), and then the dorsolateral regions of 
PAG were dissected under an anatomical microscope. Total 
protein of the PAG tissue was then extracted by homogenizing 
sample in ice-cold radioimmunoprecipitation assay buffer with 
protease inhibitor cocktail kit. The lysates were centrifuged, and 
the supernatants were collected for measurements of protein 
concentrations using a bicinchoninic acid assay reagent kit. 
The levels of IL-1β, IL-6, and TNF-α were examined using an 
ELISA assay kit (Promega Corp.) corresponding to the provided 
description and modification. Briefly, polystyrene 96-well micro-
titer immunoplates were coated with affinity-purified polyclonal 
rabbit anti-IL-1β, anti-IL-6, and anti-TNF-α antibodies. Parallel 
wells were coated with purified rabbit IgG for evaluation of 
non-specificity. After overnight incubation, the diluted samples 
and the PICs standard solutions were distributed in each plate. 
The plates were washed and incubated with anti-IL-1β, anti-IL-6, 
and anti-TNF-α galactosidase. Then, the plates were washed and 
incubated with substrate solution. After incubation, the opti-
cal density was determined using an ELISA reader. Note that 
measured absorbance on an ELISA plate reader was set at 450 
and 550 nm and subtracted 550 nm values from 450 nm values 
to correct for optical imperfections in the microplate. If 550 nm 
was not available, it was measured at 450 nm only. In the similar 
way, the levels of GABA were determined (LDN Diagnostics, 
Inc. Colorado Springs, CO, USA) according to the provided 
description and modification.
Western Blot analysis
Similar to the ELISA, dl-PAG tissues were removed. In order to 
determine the expression of PIC receptors on cell surface, PAG 
tissues were incubated with Sulfo-NHS-LC-Biotin (1  mg/ml, 
Pierce) for 30 min on ice, as described previously (26). Because 
biotin is impermeable to the cell membrane, only proteins on the 
cell surface were biotinylated. The unbound biotin in the solution 
was removed by 5× wash of PAG tissues. PAG tissues were then 
homogenized and centrifuged at 13,500 × g (4°C) for 12 min. A 
sample (200 μg protein) was incubated with streptavidin beads 
(20 μl) for 3 h at 4°C. The beads were washed 3× with RIPA buffer, 
precipitated by centrifugation, and collected. Sample buffer (50 μl) 
was added to the collected beads and boiled for 3  min. Beads 
were pelleted again by centrifugation, and the supernatant was 
collected. The supernatant was diluted to the same volume as the 
starting material (i.e., 200 μg total protein). Total and membrane 
samples in equal volume were applied to SDS-PAGE. Membranes 
were incubated with the rabbit anti-IL-1R, anti-IL-6R, and anti-
TNFR1primary antibodies (1:500, obtained from Neuromics 
and Abcam Co.). After being fully washed, the membrane was 
incubated with horseradish peroxidase-linked anti-rabbit sec-
ondary antibody (1:250) and visualized for immunoreactivity. 
The membrane was also processed to detect β-actin for equal 
loading. The bands recognized by the primary antibody were 
visualized by exposure of the membrane onto an X-ray film. The 
film was then scanned, and the optical densities of protein bands 
were analyzed using the Scion Image software. Then, values for 
densities of immunoreactive bands/β-actin band from the same 
lane were determined. Each of the values was then normalized to 
a control sample.
statistical analysis
All data were analyzed using a one-way analysis of variance. 
As appropriate, Tukey’s post hoc analyses were utilized to determine 
differences between groups. Values were presented as means ± 
SE. For all analyses, differences were considered significant at 
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P < 0.05. All statistical analyses were performed by using SPSS 
for Windows version 13.0 (SPSS Inc., Chicago, IL, USA).
resUlTs
levels of Pics and expression of Pic 
receptors
We examined the levels of PICs as well as total protein and 
membrane expression of PIC receptors in the dl-PAG of control 
rats (n = 15) and PD rats (n = 20). Figure 1A showed that IL-1β, 
IL-6, and TNF-α were elevated in PD rats as compared with 
control animals. Figures  1B–D demonstrated that the total PIC 
receptors expression in the PAG was not significantly altered in 
PD rats, but membrane PIC receptors expression was significantly 
increased in PD rats compared with control animals. Figure 1E 
further showed that the ratio of membrane and total PIC receptor 
densities was greater in the PAG of PD rats than that of control 
rats. Figure 1F shows that the ratio of membrane protein and total 
protein for IL-1R, IL-6R, and TNFR1 was 1.48 ± 0.15, 1.59 ± 0.18, 
and 1.67 ± 0.16 in PAG of PD rats (P < 0.05 vs. their respective 
controls).
Pain responses to Mechanical and 
Thermal stimuli
Mechanical withdrawal threshold and PWL appeared to be less 
in PD animals (n = 16; P < 0.05 vs. control rats) as compared 
with control rats (n =  10). We further examined the effects of 
blocking PIC receptors (respective IL-1R, IL-6R, and TNFR1) in 
the dl-PAG on PWT and PWL in PD rats (n = 12 in each group). 
Figure  2 demonstrated that PWT and PWL were significantly 
increased during a 40-min period of the test with a 10-min inter-
val after blocking each of PIC receptors (P < 0.05 vs. PD rats). 
Note that there were no differences in PWT and PWL between 
controls and PD rats with PIC receptors blocking (P > 0.05 vs. 
control rats). In addition, it is noted that blocking PIC receptors 
failed to significantly alter PWT and PWL in control animals.
engagement of gaBa
Figure 3A demonstrated that the levels of GABA were signifi-
cantly decreased in the dl-PAG of PD rats compared with control 
animals. The levels of GABA were 623 ± 21 ng/mg in control rats 
(n = 10) and 418 ± 18 ng/mg in PD rats (n = 12, P < 0.05 vs. con-
trol rats). With infusion of respective PIC receptor antagonists 
lessened, GABA was restored (n = 8 in each group, P < 0.05 vs. 
PD rats), but no significant differences were observed in GABA 
levels between control animals and PD animals with PIC recep-
tors blocking (P > 0.05 vs. control rats).
We further examined the effects of stimulation of GABAa by 
infusion of muscimol in the dl-PAG on PWT and PWL in PD 
rats. Figure 3B showed that PWT and PWL were significantly 
increased during a 40-min period of the test with a 10-min 
interval after stimulation of GABAa (P < 0.05 vs. PD rats). Also, 
no differences in PWT and PWL were observed between controls 
and PD rats with muscimol (P > 0.05 vs. control rats). This result 
suggests the engagement of GABA in hypersensitive mechanical 
and thermal responses in PD rats.
DiscUssiOn
Overall, the main findings of the present study are that (1) IL-1β, 
IL-6, and TNF-α and their receptors in membrane expression 
are upregulated in the dl-PAG of PD rats; and (2) blocking those 
individual receptors in this brain region attenuates hypersensitive 
responses to mechanical and thermal stimuli in PD rats likely by 
improving impaired GABAergic descending inhibitory system.
Nigrostriatal lesions induced by 6-OHDA in rats are widely 
used to study PD (27, 28). It has been reported that 6-OHDA 
injected into the medial forebrain bundle of rats to lead to extensive 
destruction of DA neurons of the substantia nigra pars compacta 
(29). A unilateral lesion of the nigrostriatal pathway also causes 
rotational behavior toward the lesioned side after administration 
of methamphetamine (30, 31). In the present study, the same rat 
model of PD was used, and consistent with prior studies, we have 
observed that rotational behavior appeared >7  turns/min after 
methamphetamine in 6-OHDA-injected rats.
Evidence has suggested that antinociception is mediated 
partly by descending pathways arising from the midbrain PAG 
(32, 33). Early studies showed that electrical stimulation or opi-
oids microinjected into the PAG produced profound long-lasting 
antinociception (32, 33). In particular, activated neuronal cells 
are identified in PAG of PD rats evoked by 6-OHDA (31), sug-
gesting that neural substrates are likely present within the PAG 
in engagement of the abnormalities in pain response observed 
in PD. Furthermore, previous studies showed that PIC media-
tors appear in the PAG, and activation of PICs in the PAG plays 
a role in modulating pain response or is involved in morphine 
withdrawal response (34, 35). Nonetheless, to the best of our 
knowledge, data of our present study have shown for the first 
time that PIC signal pathways in the PAG play a role in regulating 
abnormal pain response in a rat model of 6-OHDA-induced PD.
It is well-known that IL-1β is involved in the immune 
response and signal transduction both in the periphery and 
the central nervous system (36). IL-1β produced in the nerv-
ous system regulates the function of neuron and glia cells (37). 
Prior studies specifically demonstrated that IL-1β contributes 
to inflammatory and neuropathic pain (38). Increased level of 
IL-1β has been observed in the cerebrospinal fluid of chronic 
pain patients (39) and in the brainstem, contralateral thalamus/
striatum, and prefrontal cortex of rats with spared nerve injury 
(40). A recent study showed that inhibition of melanocortin 4 
receptor in the PAG not only blunts mechanical allodynia and 
thermal hyperalgesia but also delays the development of pain 
facilitation induced by peripheral nerve injury (41). This further 
decreases the expression of levels of IL-1β, IL-6, and TNF-α (41). 
Treatments with anti-IL-1β neutralizing antibodies or with IL-1β 
receptor antagonist (IL-1Ra) have also been reported to attenu-
ate or block the hyperalgesia induced by a various nociceptive 
injuries (38,  42). Consistent with these prior findings, in the 
current study, we found that membrane expression of IL-1R was 
increased in the dl-PAG of PD rats, and blocking IL-1R in this 
brain region attenuated hypersensitive responses to mechanical 
and thermal stimuli in PD rats.
IL-6 complexes with membrane-bound or soluble IL-6R to 
stimulate cells expressing the signal transducer glycoprotein 
A B C
FED
FigUre 1 | (a) Top panel: showing a rectangle area selected for the photograph of a histological section. Bottom panel: a histological section shows the location 
of injection cannula track. Arrow indicates cannula track. AQ, cerebral aqueduct; SNR, substantia nigra reticular part. (B) The levels of PICs in the dl-PAG. 
(c–e) The protein expression of PIC receptors (IL-1R, IL-6R, and TNFR1). Top panels are typical bands; bottom panels are averaged data in control rats and PD 
rats. Membrane PIC receptors are increased in PD rats, whereas total protein expression is not significantly altered. (F) The ratio of membrane PIC receptors 
protein/total PIC receptors protein. *P < 0.05 vs. control rats. The number of control rats = 15 and the number of PD rats = 20.
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(gp130) (43, 44). Most cells are lacking of membrane-bound 
IL-6R and are thus unresponsive to IL-6. Nevertheless, they still 
react to IL-6 complexed with a soluble form of the IL-6R (sIL-
6R) to activate gp130, a pathway called “trans-signaling” (44). 
Thus, in the current study, we used SC144, a gp130 inhibitor, 
to block IL-6-mediated signal transduction in order to examine 
engagement of the IL-6R in GABAergic signals and pain response 
thresholds to mechanical and thermal stimuli in PD rats.
The effects of TNF-α are via stimulation of two TNF-α recep-
tor subtypes, TNFR1 and TNFR2 (45). TNFR1 is present entirely 
on neuronal cells and plays a functional role, whereas TNFR2 
is located predominantly on macrophages and/or monocytes in 
response to inflammation. Thus, in our current study, application 
of ETAN lessens GABA in the PAG of PD rats and attenuates pain 
response, it is likely via TNFR1. In addition, we observed distinct 
expression of TNFR1 receptors in the PAG of PD rats.
FigUre 2 | effects of blocking Pic receptors in the dl-Pag on pain responses to mechanical and thermal stimulation. Mechanical and thermal 
hyperalgesia appeared lower in PD rats (n = 16) as compared with control animals (n = 10). Infusion of respective PIC receptor inhibitors into the PAG attenuated 
hypersensitive responses in PD rats (n = 12 in each group). *P < 0.05 vs. control rats and PD rats that received infusion of inhibitors over a 40-min testing time 
(indicated by gray bars).
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Microglia are one of the major cell types involved in the 
inflammatory responses in the central nervous system (46). The 
evidence from a prior study revealed reactive microglia in the 
substantia nigra pars compacta of human postmortem brain 
tissue, suggesting the involvement of neuroinflammation in PD 
pathogenesis (47). Prior reports using positron emission tomog-
raphy (PET) have further indicated that there are amplified activi-
ties of microglia in various brain regions of PD patients (12, 14). 
Moreover, activation of microglia in the substantia nigra pars 
compacta and striatum is amplified in various types of PD animal 
models (13, 48). Biochemical analysis also showed exaggerated 
pro-inflammatory mediators, including IL-1β and TNF-α, in the 
midbrain of PD patients (49). These data indicate the involvement 
of immune mechanisms in PD pathophysiological process.
In addition, prior studies showed that astrocytes play an 
important role in regulating the neuroinflammatory response in 
PD. Similar to microglia, astrocytes react to the inflammatory 
stimulations by producing PICs, including IL-1β and TNF-α, 
both in vitro and in vivo (46, 50). Reactive astrogliosis with the 
increased glial fibrillary acidic protein, hypertrophy of cell body 
and cell extensions has been found in PD animal models (51).
In the present study, we demonstrated that cell membrane PIC 
receptors are upregulated in the dl-PAG of PD rats. However, the 
total protein expression of PIC receptors was not considerably 
altered in the PAG of PD rats, indicating that PIC receptors 
trafficking to the cell membrane of PAG is particularly amplified 
in PD rats (26). The underlying mechanism for the increase in 
trafficking of PIC receptors following 6-OHDA lesions needs 
to be determined. The elevated PICs were also observed in PD 
rats in the present study. Accordingly, we assume that PICs are 
likely released from the glial cells, and this signal is likely to lead 
to upregulation of membrane PIC receptors. Nevertheless, it is 
speculated that the increased activities in the PIC pathways are 
likely to result in neuronal loss within the PAG since PICs is 
engaged in the process of apoptosis, which has been observed in 
PD brains (52).
Interestingly, results of our present study further demonstrated 
that the levels of GABA were significantly decreased in the dl-PAG 
of PD rats. Prior studies showed antinociceptive effects evoked 
by stimulation of this region of PAG (7, 9). This supports our 
hypothesis that activation of PIC receptors within the PAG plays 
a de-inhibitory role in regulating the descending pain pathways. 
When PIC receptors are blocked in the dl-PAG, the abnormal 
descending pain pathways are largely restored because we have 
observed that chronic infusion of PIC antagonists lessened ampli-
fied pain responses in PD animals accompanied with increasing 
GABA levels in the PAG. Furthermore, our results found that 
mechanical and thermal hyperalgesia in PD rats was attenuated 
following stimulation of GABAa receptors in the dl-PAG by 
infusion of muscimol, suggesting that PIC receptors influence 
AB
FigUre 3 | (a) The levels of GABA in the dl-PAG. The GABA was significantly diminished in PD rats (n = 12) as compared with control animals (n = 10). Injection of 
respective PIC receptor inhibitors largely restored impaired GABA. *P < 0.05 vs. control rats and rats with infusion of PIC receptor inhibitors (n = 8 in each group). 
(B) Effects of stimulation of GABAa receptors in the dl-PAG on pain responses to mechanical and thermal stimulation. Mechanical and thermal hyperalgesia 
appeared in PD rats (n = 10) as compared with control animals (n = 8). Infusion of GABAa receptor agonist, muscimol, into the PAG attenuated hypersensitive 
responses in PD rats (n = 12). *P < 0.05 vs. control rats and PD rats with infusion of muscimol over a 40-min testing time (indicated by gray bars).
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GABAergic transmission within this region of PAG and thereby 
amplify pain response.
We speculate that there are some possibilities that PICs and/
or activation of PIC receptors can alter GABAergic pathway 
(53). (1) PICs inhibit the releases of GABA in the dl-PAG since a 
lower level of GABA was observed in this region in our current 
study; (2) the increased PICs are likely to damage neurons of the 
dl-PAG thereby leading to a reduction in GABA; (3) the ampli-
fied membrane PIC receptors observed in our study are likely 
to modulate activities of ion channels on neurons of the dl-PAG 
and decrease the GABA levels or attenuate GABAergic transmis-
sion. Additional studies need to determine a precise mechanism 
responsible for how PICs alter GABAergic pathway within the 
dl-PAG in involvement of abnormal pain responses in PD.
study limitations
In the current study, we examined the levels of PICs and their 
respective receptors in the PAG of control rats and rats injected 
with 6-OHDA, and then examined if blocking PIC receptors 
affected pain response and the levels of GABA. Our results showed 
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that PIC pathway in the PAG of 6-OHDA-rats was upregulated 
by using Western Blotting and ELISA, but we did not perform 
the immunohistochemical experiment to indicate this result. 
We assumed that the effects of 6-OHDA on GABA were likely 
indirect via PICs signal. In addition, the previous studies have 
demonstrated that dopamine levels were decreased in SNc by 
6-OHDA (31). Thus, we did not perform the immunohistochemi-
cal experiment to indicate this result in our current study. We 
must knowledge that those issues should be considered as study 
limitations, and adding this line of results obtained by immuno-
histochemical experiment would strengthen our current findings.
In conclusion, we have shown that the membrane PIC 
receptors are increased in the dl-PAG of PD rats and thereby 
de-inhibit GABAergic mediated-descending regulation in pain 
transmission. These abnormalities are likely to contribute to the 
development of mechanical and thermal hypersensitivity in PD 
animals. Results of this study provided a base for the mechanisms 
responsible for PD-induced pain. This further offers promising 
clues to target central nerve system for the development of new 
therapeutic strategies for managing intractable pain response in 
PD patients.
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